Veralox Therapeutics
Veralox is a clinical stage biotechnology company focused on developing first-in-class small molecule therapeutics targeting the 12-Lipoxygenase and cGAS pathways to treat life-threatening immuno-inflammatory diseases. With a proven track record of over 30 development candidates, 22 INDs, and 10 NDAs, Veralox aims to improve clinical outcomes for diseases like Heparin-Induced Thrombocytopenia (HIT) and Type 1 Diabetes (T1D). The company is advancing its pipeline with innovative therapies and strategic acquisitions, such as the exclusive option to acquire Nudge Therapeutics.
Industries
Nr. of Employees
small (1-50)
Veralox Therapeutics
Products
VLX-1005
A first-in-class small molecule drug targeting 12-Lipoxygenase, developed for treating Heparin-Induced Thrombocytopenia (HIT). It has received Fast Track designation from the FDA.
VLX-2000
A series of small molecule therapeutics targeting Type 1 Diabetes and other undisclosed indications.
VLX-1005
A first-in-class small molecule drug targeting 12-Lipoxygenase, developed for treating Heparin-Induced Thrombocytopenia (HIT). It has received Fast Track designation from the FDA.
VLX-2000
A series of small molecule therapeutics targeting Type 1 Diabetes and other undisclosed indications.